Genome Engineering Market, by Technology (CRISPR, TALEN, ZFN, and others), by Application (Cell Line Engineering, and Genetic Engineering), by End User (Biotechnology & Pharmaceutical Companies, Research Institutes, and Contract Research Organizations) an

Genome Engineering Market, by Technology (CRISPR, TALEN, ZFN, and others), by Application (Cell Line Engineering, and Genetic Engineering), by End User (Biotechnology & Pharmaceutical Companies, Research Institutes, and Contract Research Organizations) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Genome engineering is a process of insertion, deletion, modification or replacement of Deoxyribonucleic acid (DNA) bases in an organism. There are two types of gene therapy, Ex-Vivo gene therapy and In-Vivo gene therapy. Ex-vivo gene therapy involves the transfer of genes in cultured cells and then reintroducing in patient, while in In-vivo gene therapy, genes are directly delivered in cells of a particular tissue. Key companies such as CRISPR Therapeutics AG, Editas Medicine, Inc., and Intellia Therapeutics, Inc. are focusing on developing In-Vivo and Ex-vivo gene therapy. Major techniques used in genome engineering are Clustered regularly interspaced short palindromic repeats (CRISPR), Transcription activator-like effector nucleases (TALEN), and Zinc-finger nucleases (ZFNs). These are innovative genome editing tools that enable researchers to edit parts of the genome by adding, removing, or altering sections of the DNA sequence. CRISPR is an accurate, faster, and cheaper technique for editing DNA as compared to other methods such as TALEN and ZFN. Transcription activator-like effector nucleases (TALEN) is a technology widely used in live cell gene editing. Zinc-finger nucleases (ZFNs) is an artificial restriction enzyme, which simplifies targeted editing of genome by creating double-strand breaks in DNA at user-specified locations.

Market Dynamics

Increasing strategic collaboration for genome engineering technologies by key players is expected to drive market growth over the forecast period. Key players in market are focusing on strategic collaborations, in order to increase their product offerings. For instance, in February 2018, Kite Pharma, Inc., a Gilead Sciences, Inc. company, collaborated with Sangamo Therapeutics Inc. for developing engineered cell therapies to treat cancer. As per the agreement, Kite Pharma, Inc. would use Sangamo Therapeutics’ zinc finger nuclease (ZFN) gene-editing technology for developing next-generation ex vivo cell therapies for treatment of cancer. Furthermore, in 2017, Synthego and Thermo Fisher Scientific collaborated to manufacture and distribute synthetic guide ribonucleic acid (RNA) products for CRISPR genome engineering.

Key features of the study:

• This report provides an in-depth analysis of the global genome engineering market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global genome engineering market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Thermo Fisher Scientific Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Editas Medicine, Inc., Sangamo Therapeutics, Inc., Bluebird Bio, Inc., Cellectis S.A., and Merck Group
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global genome engineering market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global genome engineering market

Detailed Segmentation:

• Global Genome Engineering Market, By Technology :
• CRISPR
• TALEN
• ZFN
• Others
• Global Genome Engineering Market, By Application:
• Cell Line Engineering
• Genetic Engineering
• Global Genome Engineering Market, By End User:
• Biotechnology & Pharmaceutical Companies
• Research Institutes
• Contract Research Organization
• Global Genome Engineering Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region/Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Thermo Fisher Scientific Inc.*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• CRISPR Therapeutics AG
• Intellia Therapeutics, Inc.
• Editas Medicine, Inc.
• Sangamo Therapeutics, Inc.
• Bluebird Bio, Inc.
• Cellectis S.A.
• Merck Group

“*” marked represents similar segmentation in other categories in the respective section.